Squarepoint’s Biolase, Inc. BIOL Stock Holding History

Squarepoint’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7	Closed	-$15K	–	3816
2021 Q1	$15K	Sell	7 -199	-97%	-$489K	﹤0.01%	3033
2020 Q4	$215K	Buy	+206	New	+$157K	﹤0.01%	2458

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Squarepoint's BIOL Position: Q2 2021 in Review

Squarepoint sold out of Biolase, Inc. (BIOL) in Q2 2021, closing a stake of 7 shares — an estimated $15K sold.

Squarepoint first reported a position in BIOL in Q4 2020 and held it in 2 quarters. The position peaked at $215K in Q4 2020. 31 funds tracked by Wall St. Rank hold BIOL as of Q2 2021.

Squarepoint reported no remaining Biolase, Inc. position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 7 Biolase, Inc. shares in Q2 2021, an estimated $15K.
Squarepoint first reported a position in Biolase, Inc. in Q4 2020 and held it in 2 quarters.
Squarepoint's Biolase, Inc. position peaked at $215K in Q4 2020.
31 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.